- Immunovant (IMVT, Financial) appoints new CEO and CFO amid strategic expansion.
- IND clearance received for IMVT-1402 in Sjögren's Disease and study initiated in Cutaneous Lupus Erythematosus.
- Current cash reserves secure operations through 2027 Graves' Disease readout.
Immunovant, Inc. (IMVT), a clinical-stage immunology company, has announced significant changes in its leadership team as part of its strategic growth initiative. Eric Venker, M.D., previously President and COO of Roivant, is appointed the new CEO of Immunovant, succeeding Pete Salzmann, M.D., who has retired. Additionally, Tiago Girao steps in as CFO, replacing Renee Barnett.
The company has secured IND clearance for a potentially registrational program for its compound IMVT-1402 in treating Sjögren's Disease (SjD), marking the fifth indication for the drug. Clinical studies are planned to commence by the summer of 2025. Furthermore, Immunovant has launched a proof-of-concept study targeting Cutaneous Lupus Erythematosus (CLE), extending the IMVT-1402 development program to six indications.
Immunovant confirmed that its current cash reserves would sustain its operations through to the anticipated readout for Graves' Disease in 2027. This cash runway ensures the company's stability and commitment to advancing IMVT-1402's development across multiple indications. The leadership overhaul aligns with Roivant's increased strategic involvement and operational oversight of Immunovant.
